Individually Titrated High-dose Baclofen for the Treatment of Alcohol Dependence (baclad Study) – a Randomized Controlled Trial - 09/06/15
Résumé |
Introduction |
Preclinical and first clinical studies suggested that the selective γ-aminobutyric acid (GABA)-B receptor agonist baclofen might be effective in the treatment of alcohol dependence. However, previous randomized controlled trials have reported inconsistent results, possibly related to the low to medium dosages of baclofen used in these studies.
Objectives |
To assess the efficacy and safety of individually titrated high-dose baclofen (30-270 mg/d) for the treatment of alcohol dependence.
Methods |
Fifty-six alcohol-dependent patients were randomized to a double-blind treatment with individually titrated baclofen or placebo. Multiple primary outcome measures were total abstinence and cumulative abstinence duration during a 12-week high-dose phase.
Preliminary results of this clinical trial will be presented.
Le texte complet de cet article est disponible en PDF.
Vol 30 - N° S1
P. 1611 - mars 2015 Retour au numéro
Article précédent
- Assessment of the Efficacy of First and Second Generation of Depot Neuroleptics
- M. Spremo, L.J. Babic, M. Savic
- Evaluation of Pharmacists’ Opinion and Knowledge Regarding Generic Medicinal Products in Poland.
- G. Cessak, E. Balkowiec-Iskra
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?